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The lower respiratory tract is repetitively inocu- 
lated with oropharyngeal bacteria and yet pneu- 
monia is an infrequent event. Efficient mecha- 
nisms of antibacterial defense are present in the 
respiratory tract that eliminate microbes before 
their presence or multiplicatjon leads to disease 
in the majority of instances, Resident uulmonary 
defenses consist of aerodynamic defenses, the 
mucociliary apparatus, alveolar macrophages, 
complement, and surfactant. These resident de- 
fenses can be augmented by the development of 
an inflammatory response or the development of 
specific immunity. Significant species variability 
exists in the efficiency and mechanisms of clear- 
ance for oropharyngeal organisms. Streptococci 
are cleared promptly, Branhamella catarrhalis is 
cleared slowly, whereas non-typable Haemophilus 
influenzae multiply before being cleared. A .dual 
phagocytic system of alveolar macrophages and 
recruited polymorphonuclear leukocytes is re- 
quired for clearance of most oropharyngeal mi- 
crobes. Systemic immunization can significantly 
enhance clearance of non-typable H. influenzae, 
suggesting immunoprophylaxis might be possible 
for this organism. 
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T he largest epithelial surface exposed to the envi- ronment is the lung. Although the lung is continu- 
ously exposed to inspired air that contains microbes, 
early bacteriologic studies of bronchoscopically ob- 
tained tracheobronchial secretions and of lung biopsy 
material cultured at the time of thoracotomy sug- 
gested that the lung was a sterile organ [l-3]. This 
traditional concept of a continuously sterile lung has 
been challenged by more recent observations. Post 
mortem cultures of lung tissues obtained from previ- 
ously healthy persons who died suddenly yielded small 
numbers of bacteria similar to those cultured from the 
pharynx [4]. Similarly, microbiologic studies of normal 
dogs showed that 89 percent of the lungs contained 
oropharyngeal organisms despite, a study design that 
prevented agonal aspiration of upper respiratory tract 
secretions [5]. Finally, it has been demonstrated that 
pharyngeal contents enter the lower respiratory tract 
of normal persons during sleep. Pharyngeal secretions 
were noted in the lungs of 45 percent of normal per- 
sons and 70 percent of patients with altered conscious- 
ness. All normal subjects who slept soundly through- 
out the night aspirated oropharyngeal secretions. The 
foci of localized deposits of pharyngeal contents de- 
tected in human lungs and the foci of bacteria isolated 
from normal dog lungs were distributed in both 
gravity- and non-gravity-dependent areas [5,6] which 
suggests that both aspiration and aerosohzation of 
pharyngeal secretions are responsible for the deposi- 
tion of bacteria from the oropharynx into the lung. 
The number of bacteria inoculated into the lungs of 
normal persons is unknotin. Two possibilities could 
account for the small number of bacteria isolated from 
normal lungs. A small number of bacteria might be 
deposited in the lung during sleep but cleared slowly, 
or many organisms might be deposited but cleared 
rapidly. The high density of bacteria in pharyngeal 
secretions suggests the latter [‘7,9]. Small volumes of 
oropharyngeal material can provide a significant inoc- 
ulum of bacteria. Oropharyngeal bacteria are present 
in up 
of 10 B 
er respiratory tract secretions in concentrations 
bacteria/ml; therefore, aspiration of only 0.01 ml 
would inoculate lo5 bacteria into the lower respiratory 
tract. These data suggest the existence of efficient 
mechanisms of defense that are capable of eliminating 
micro-organisms before their multiplication leads to 
disease. 
The components of the pulmonary host defenses are 
distributed throughout the respiratory tract. Aerody- 
namic filtration and impaction occur in the nose, which 
removes large particulates, and cough and neurologic 
reflexes are important in the prevention of aspiration. 
In the lower respiratory tract, defenses include the 
mucociliary apparatus, alveolar macrophages, comple- 
ment, and surfactant. All of these defenses are pres- 
ent at all time in normal persons and comprise the res- 
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Figure 1. Determinants of bacterial clearance. 
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The fraction of bacteria remaining in the lung are 
shown at various time points. The heavy black 
line depicts net bacterial clearance, which is the 
variable measured in most clearance experi- 
ments A small portion of the total decrease is 
due to physical removal by the mucociliary ap- 
paratus. The lower line represents the com- 
bined effects of mucociliary clearance and in 
situ hilling in the absence of bacterial multiplica- 






ident defenses of the lungs. These resident defenses 
deal with day-to-day challenges and effectively clear 
small inocula of bacteria. However, the combination of 
cough, niucociliary clearance, and alveolar macro- 
phage phagocytosis is inadequate for clearance of 
large inocula of virulent bacteria. Under these circum- 
stances, resident defenses are augmented by the rapid 
development of a pulmonary inflammatory response 
[lO,ll]. Additionally, specific immune responses may 
be generated leading to the production of specific 
immunoglobulins and to cell-mediated immunity. 
ANIMAL MODEL SYSTEMS 
The concept of an antibacterial defense system in- 
trinsic to the pulmonary parenchyma was established 
utilizing an animal model at the turn of the century 
[12]. Animal models continue to be used extensively 
because the lower respiratory tract is unique with 
regard to phagocytic populations, levels of both immu- 
noglobulin and complement [13-151, and the induction 
of immunity [15-201. A well-characterized murine 
model system has been utilized to study the clearance 
of bacteria from the lung. Utilizing this model, the 
entire sequence of events involved in bacterial clear- 
ance can be studied in vivo. 
Bacteria can be deposited in the lower respiratory 
tract by exposure to a bacterial aerosol or by an intra- 
tracheal or intrabronchial injection of fluid containing 
micro-organisms [21,22]. The foci of localized deposits 
of pharyngeal contents detected in human lungs and 
the foci of bacteria isolated from normal dog lungs 
were distributed in both gravity- and non-gravity- 
dependent areas [5,6], which suggests that both aspi- 
ration and aerosolization of pharyngeal secretions are 
responsible for the deposition of oropharyngeal bacte- 
ria into the lung. Either technique delivers a suffi- 
ciently precise and reproducible inoculum of bacteria 
to allow quantitation of bacterial clearance over ex- 
tended time intervals and neither inoculation alters 
lung architecture. Following aerosol exposure, bacte- 
ria are widely dispersed throughout the lung, and the 
ratio of bacteria to resident phagocytes is low, 
whereas bolus inoculation deposits bacteria in a local- 
1 
ized area of parenchyma and results in a higher bac- 
teria-to-phagocyte ratio. At various time points after 
inoculation, the lungs of infected animals are removed 
and homogenized, and serial dilutions of the homoge- 
nates are plated on agar in order to quantify the num- 
ber of viable bacteria remaining in the lung. In most 
experiments, several time points after inoculation are 
evaluated. The decline in bacteria (clearance) is the 
net result of three processes: mucociliary clearance, 
bacterial killing, and bacterial multiplication (Figure 
1). Net clearance is the variable evaluated in in vivo 
experiments. Although bacterial clearance can be al- 
tered by changes in any of these processes, bacterial 
killing appears to be the rate-limiting process. In cir- 
cumstances where killing is exceeded by bacterial 
multiplication rates, net increases in bacteria isolated 
from the lung will occur [23-251. 
This animal model can also be used to evaluate the 
development of a pulmonary inflammatory response 
or the development of pulmonary immunity. Utilizing 
bronchoalveolar lavage, the number and types of cells 
present in the air spaces can be determined. The la- 
vage fluid can be assayed for the presence of chemo- 
taxins and immunoglobulins. Adequate numbers of 
cells are obtained for the performance of functional 
cellular studies or for the performance of in vitro stud- 
ies of secreted cell products. A particularly attractive 
feature of this animal model is the ability to assess 
both the induction of the response (inflammation, 
immunity) and its expression in the lung. The model 
allows determination of whether the effecters (anti- 
bodies! cells) are delivered to the site of the host- 
bacterial interaction and whether they are functional 
(i.e., protective) in the lung. 
CLEARANCE OF OROPHARYNGEAL BACTERIA 
FROM THE LUNGS 
Bacteria are normally present in the oropharynx 
and in saliva of humans and animals. Viridans strepto- 
cocci (Streptococcus salivarius and Streptococcus san- 
gius) and aerobic gram-negative organisms (Bran- 
hamella catarrhalis and nontypable Haemophilus 
influenxae) are normally present in the oropharynx 





Percentage of Bacteria Remaining 
1 Hour 2 Hours 4 Hours 
S. sangus 4.7 k 0.3 24.0 2 2.0 8.0 IT 1.0 1.0 i 0.0 
S. salivarius 3.9 * 0.2 49.0 f 3.0 24.0 i: 3.0 5.0 * 0.0 
B. cafarrhalis 4.5 k 0.2 69.0 i 9.0. 49.0 f 4.0 22.0 i 2.0 
CFU = colony-forming units. 
*Each value represents a mean of 15 to 18 animals at each interval; data are mean t 
SEM. 
Data are reprinted with permission from [26]. 
TABLE II I 
Phagocytic Cell Response* / 
Time after Aerosol 
0 Hours 2 Hours 4 Hours 
S. sanguis 
Alveolar macrophaqes x lo5 9.3 i- 1.3 196. f 1.4 




0.4 2 0.4 
S. salivarjus 
Alveolar macropha$es x lo5 10.3 * 0.6 13.2 f. 0.9 12.3 i: 1.0 
Granulocytes x 10 0.4 * 0.2 7.6 * 2.3 8.4 ? 2.4 
B. catarrhalis 
Alveolar macrophaies x lo5 1;:; T a? 12.7 ?r 1.4 11.7 i 1.1 
Granulocyies x 10 + 3.4 * 0.8 40.9 + 5.5 
Data are mean f SEM. 
ata are reprinted with permission from [26]. 
and in the saliva of humans and animals [7-g]. There 
are significant species differences in the clearance of 
these organisms. Ninety-five percent of aerosolized 
streptococci were eliminated within four hours, 
whereas aerosolized B. catarrhalis was cleared at a 
slower rate (Table I) [26]. Following bolus inoculation 
of non-typable H. influenxae (NTHI), a biphasic pat- 
tern was observed. During the first six hours after 
inoculation with NTHI, bacterial multiplication ex- 
ceeded killing and the number of bacteria increased 
fourfold (395 + 32 percent). During the second phase, 
killing exceeded multiplication and the bacteria were 
eradicated within 24 hours (2 percent bacteria remain- 
ing) [2’7]. These results indicate that resident defenses 
in mice are unable to effect eradication of oropharyn- 
geal organisms and must be augmented for clearance 
to occur. 
PHAGOCYW CELL RESPONSE ~0 
OROPHARYNGEAL BACTERIA 
Phagocytic cells are importantly involved in bacte- 
rial killing in the lung. Bronchoalveolar lavage of nor- 
mal, water-aerosolized and water-bolus-inje:ted mice 
resulted in similar numbers of phagocytes (approxi- 
mately 9 to 10 x 105). Alveolar macrophages appear 
to be the only phagocyte involved in the clearance of 
S. sangius. A doubling in the number of alveolar mac- 
rophages was noted within four hours after inocula- 
tion of S. sangius. Studies of changes in alveolar cell 
populations after challenge with S. salivar-ius, B. ca- 
tarrhalis, and NTHI suggest that recruitment of holy- 
morphonuclear leukocytes (PMN) is required to aug- 
ment resident host defenses [26,271. Challenge with $. 
salivarius resulted in a ZO-fold increase in the numb& 
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of PMN at four hours, and challenge with B. catarrh- 
aEis resulted in a 400-fold increase in PMN (Table II). 
Challenge with NTHI resulted in loo-fold increase in 
total cells at six hours. No PMNs were present in al- 
veolar lavage at zero hours, whereas 1.7 x lo6 PMN 
were isolated at six hours. At six hours? PMN cotisti- 
tuted 63 percent of the phagocytic cells m the alveolar 
lavage. Thus, both alveolar macrophages and PMN 
are apparently important in the clearance of most oro- 
pharyngeal bacteria. 
Studies of neutropenic mice have demonstrated the 
importance of recruited PMN to clearance of NTHI 
[28]. Systemic treatment of mice with nitrogen mus- 
tard resulted in profound neutropenia but did not alter 
the numbers of resident alveolar macrophages. Nitro- 
gen mustard-treated mice were unable to recruit 
PMN into the lungs after NTHI challenge, and pulino- 
nary clearance of NTHI was significantly impaired in 
these neutropenic animals. These data demonstrate 
that recruited PMN are a major component of the 
early defense against NTHI and are crucial for effec- 
tive clearance of this oropharyngeal organism. Al- 
though similar studies have not been performed fol- 
lowing challenges with other oropharyngeal organ- 
isms, these data suggest that PMN are important to 
early clearan@e of those organisms that result in their 
recruitment. 
MECHANISMS OF PMN RECRUITMENT 
The ability to develop an inflammatory response is a 
fundamental part of the pulmonary response to bacte- 
ria. The initiation of an inflammatory response in- 
volves the generation of intra-alveolar chemotaxis 
[29]. The specific chemotactic factors responsible for 
PMN recruitment following challenges with oropha- 
ryngeal organisms have been psrtially characterized 
using congenic C5-sufficient BlO.D2/nSn (C5+) and 
C5-deficient BlO.DB/nSn (C5-) mice. The C5- mice 
recruited significantly fewer PMN following chal- 
lenges with NTHI than C5+ mice. The impaired in- 
flux of PMN into the lungs of C5- mice paralleled 
impaired clearance of NTHI. Thus, the C5 molecule 
and its fragments are important chemotaxins during 
the first six hours after exposure to oropharyngeal 
organisms [28]. 
Although PMN recruitment was significantly im- 
paired during the first six hours following NTHI chal- 
lenge in C5- mice, the C5- mice recruit near-normal 
numbers of PMN to the lung at 24 hours. The nature 
of the non-C5 chemotactic factors is speculative but 
probably includes alveolar macrophage-derived 
cytokines [30-331 and macrophage-generated prod- 
ucts of the lipoxygenase pathway such as leukotriene 
Bq, and 5- or ll-monohydroxyeicosatetraenoic acid 
[34,35]. Alveolar macrophages have the capacity to 
metabolize endogenous arachidonic acid, mobilized by 
agonist stimulation, into substantial amounts of 
5-lipoxygenase (5-LO) products. Monocytes are un- 
able to metabolize endogenous arachidonic acid into 
5-LO products. This inability to generate 5-LO prod- 
ucts is due to a lack of coupling between arachidonic 
acid deacylated by phospholipase and the 5-LO en- 
zyme. By contrast, the degree of coupling between 
arachidonic acid release and 5-LO metabolism in- 
creases dramatically with different,iation of monocytes 
to alveolar macrophages in the lung. This alteration in 
5-LO metabolism of endogenous arachidonic acid, 
which occurs with differentiation of monocytes to al- 
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veolar macrophages, is important in equipping alveo- 
lar macrophages with the ability to mount an inflam- 
matory response in the alveolar space [361. 
Alveolar macrophages also secrete numerous 
cytokines? which are important in neutrophil accumu- 
lation. Stimulated alveolar macrophages produce both 
interleukin-1 (IL-l) and tumor necrosis factor (TNFa) 
[37,38]. Initial reports suggested these cytokines 
were chemotactic for neutrophils [39], but recent 
studies have shown that neither recombinant IL-l nor 
TNF has direct chemotactic activity in vitro for neu- 
trophils [40]. Alveolar macrophages have also been 
shown to generate a low molecular weight chemotactic 
factor after phagocytosis of microbes that preferen- 
tially attracts neutrophils [31-331. This alveolar mac- 
rophage-derived neutrophil chemotactic factor is simi- 
lar to a recently isolated and cloned monocyte NCF 
[41]. The complete nucleotide sequence of the comple- 
mentary deoxyribonucleic acid of monocyte-derived 
NCF has recently been published. This complemen- 
tary deoxyribonucleic acid encodes a 99-amino acid 
protein with an estimated molecular weight of 8,000 
daltons for the active species. The amino acid se- 
quence of monocyte-derived NCF shows a high de- 
gree of homology with other molecules involved in in- 
flammation and cell growth such as beta-thromo- 
globulin and platelet factor 4 [42,431, suggesting this 
factor may be a member of a supergene family. 
Lipoploysaccharide, interleukin-1, and tumor necrosis 
factor have all been shown to increase monocyte- 
derived NCF steady state m-RNA within one hour 
and cause the production of biologically active NCF by 
monocytes [41]. Recent studies have shown that alve- 
olar macrophages increase cellular steady-state NCF 
m-RNA and produce biologically active NCF in re- 
sponse to LPS (Strieter RM, et al, submitted for pub- 
lication). 
Recent studies have demonstrated that non-im- 
mune cells may participate in the generation of a pul- 
monary inflammatory response by the synthesis of a 
chemotactic factor similar to monocyte-derived NCF. 
Human endothelial cells produce a NCF with molecu- 
lar and physiochemical characteristics consistent with 
monocyte-derived NCF following stimulation with 
tumor necrosis and interleukin-1B or lipopolysaccha- 
ride [44]. More recently, fibroblasts have been shown 
to have dose-dependent increases in steady-state 
m-RNA and to secrete a NCF similar to monocyte- 
derived NCF following exposure to TNFa(, IL-lB, or 
IL-la. In contrast, LPS and interleukin-6 failed to 
induce fibroblast-derived NCF [45]. Finally, IL-la, 
IL-l?, and TNFa have been shown to induce the ex- 
pression of high levels of NCF m-RNA in a type II- 
like epithelial cell line (A549). Interestingly, LPS had 
no effect on the induction of NCF in epithelial cells 
(Strieter RM, et al, submitted for publication). 
The entry of bacteria or bacterial products into the 
lower respiratory tract initiates a complex series of 
events that results in the recruitment of PMN to the 
lung (Figure 2). The initiation of the inflammatory 
response involves several mechanisms including C-5- 
derived chemotactic peptides, a cascade of macro- 
phage-derived cytokines, and arachidonic acid metab- 
olites and cytokines produced by non-immune cells of 
the alveolar-capillary membrane. It seems likely that 
different chemotaxins are generated in sequence such 
that some factors are involved in the early phases, 
whereas others are important at later time points. 
Flgure 2. Mechanism ot granulocyte recruitment to the lung. The entry of bacteria 
or bacterial products into the lower respiratory tract initiates a complex series of 
events that iesults in the recruitment oi PMN- to the lung. 
TABLE III 
Effect of Systemic Immunization with an Outer Membrane 
Protein/LPS Complex on Pulmonary Clearance of NTHI 
Percent Bacteria Remaining 
Immune Status at 6 Hours Post Challenge 
Control 358 i 30 
Immune 162 1 
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TABLE IV 
Effect of Intravenous Administration of a LPS-Specific 
Monoclonal Antibody on Pulmonary Clearance of NTHI 
Cd-derived peptides are important in the first six 
hours following bacterial entry, whereas macrophage 
and non-immune cell-derived NCFs are likely impor- 
tant at later time points. Although a variety of cellular 
components in the lung can express NCF, this expres- 
sion is stimulus-specific. Both endothelial cells and 
alveolar macrophages can express NCF m-RNA and 
functionally active NCF in response to primary bacte- 
rial products such as LPS. Alternatively, fibroblasts 
and type II epithelial cells only produce NCF in re- 
sponse to alveolar macrophage- and monocyte-induced 
cytokines, IL-1 and TNF. The coordinated participa- 
tion of mononuclear phagocytes, endothelial cells, fi- 
broblasts, and epithelial cells is likely required for the 
generation of the chemotactic gradient required for 
PMN recruitment. 
SPECIFIC HUMORAL IMMUNITY 
Normal bronchoalveolar washings contain immuno- 
globulin G (IgG) and IgA [461, but it is uncertain what 
role immunoglobulin plays in resident defenses within 
the alveolus. Normal mice have been shown to have no 
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specific serum antibodies against normal oropharyn- 
geal flora [26,47]. Although the role of immunoglobu- 
lin in resident pulmonary antibacterial defenses is 
uncertain, it is clear that immunization can enhance 
early clearance of bacteria from the lower respiratory 
tract. Systemic immunization with NTHI resulted in 
NTHI-specific antibody in both serum and bronchoal- 
veolar lavage. The concentration of NTHI-specific 
antibody in serum of immunized animals was l,OOO- 
fold higher than in serum of controls, whereas the con- 
centration of NTHI-specific antibody in bronchoalveo- 
lar lavage was at least 200-fold greater than in bron- 
choalveolar lavage obtained from control animals. 
Western blot analysis revealed that the specificities of 
antibodies in bronchoalveolar lavage were identical 
with those of antibodies in the serum demonstrating 
that serum IgG can enter the alveolar spaces of the 
uninflamed lung, probably by transudation. Thus, di- 
rect airway immunization is not required to generate 
protective, specific antibody in the air spaces of the 
lung [471. 
An acellular NTHI antigen preparation has also 
been shown to generate protective antibodies in the 
air spaces. Mice immunized with an outer membrane 
protein-lipo-oligosaccharide complex produced anti- 
bodies directed against both immunogens and the 
presence of these antibodies was correlated with a 
marked enhancement of pulmonary clearance of 
NTHI (Table III). Although these data do not allow a 
determination of the role of cellular versus humoral 
immunity, passive intravenous immunization of mice 
with a LPS-specific monoclonal antibody resulted in 
markedly enhanced lower respiratory tract clearance 
of NTHI (Table IV) [48]. Taken together, these data 
suggest that immunoprophylaxis or immunomodula- 
tion of NTHI disease in the lungs is feasible. 
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